Long-acting erythropoietin: Clinical studies and potential uses in neonates

Clinics in Perinatology

Volumn 31, Issue 1, 2004, Pages 77-89

  Ohls, Robin K ^a   Dai, Aihua ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

DIARRHEA; DRUG FEVER; DRUG HALF LIFE; DRUG SAFETY; EDEMA; FATIGUE; HEADACHE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; HYPOTENSION; MALIGNANT TRANSFORMATION; MYALGIA; NAUSEA; NEWBORN; NEWBORN ANEMIA; PREMATURITY; PRIORITY JOURNAL; PRURITUS; REVIEW;

ADULT; ANEMIA; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; NEOPLASMS; PEDIATRICS; RANDOMIZED CONTROLLED TRIALS; TECHNOLOGY, PHARMACEUTICAL;

EID: 2942588865     PISSN: 00955108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clp.2004.03.006     Document Type: Review

References (32)

1. Egrie J.C., Dwyer E., Lykos M., Hitz A., Browne J.K. Novel erythropoiesis stimulating protein (NESP) has a longer serum half life and greater in vivo biological activity than recombinant human erythropoietin. Blood. 90:1997;56a
2. Egrie J.C., Browne J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer. 84(Suppl):2001;3-10
3. Egrie J.C., Dwyer E., Browne J.K., Hitz A., Lykos M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 31:2003;290-299
4. Macdougall I.C., Gray S.J., Elston O., Breen C., Jenkins B., Browne J., Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 10:1999;2392-2395
5. Locatelli F., Olivares J., Walker R., Wilkie M., Jenkins B., Dewey C., et al. European/Australian NESP 980202 Study Group Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 60:2001;741-747
6. Allon M., Kleinman K., Walczyk M., Kaupke C., Messer-Mann L., Olson K., et al. Pharmacokinetics and pharmacodynamics of darbepoietin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 72:2002;546-555
7. Nissenson A.R., Swan S.K., Lindberg J.S., Soroka S.D., Beatey R., Wang C., et al. Randomized, controlled trial of darbepoietin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 40:2002;110-118
8. Vanrenterghem Y., Barany P., Mann J.F., Kerr P.G., Wilson J., Baker N.F., et al. European/Australian NESP 970200 Study Group Randomized trial of darbepoietin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 62:2002;2167-2175
9. Macdougall I.C., Matcham J., Gray S.J. NESP 960245/246 Study Group Correction of anaemia with darbepoietin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant. 18:2003;576-581
10. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 346:2002;469-475
11. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003;18(Suppl):viii, 37-41
12. Glaspy J.A., Jadeja J.S., Justice G., Fleishman A., Rossi G., Colowick A.B. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 97:2003;1312-1320
13. Hedenus M., Adriansson M., San Miguel J., Kramer M.H., Schipperus M.R., Juvonen E., et al. Darbepoetin Alfa 20000161 Study Group Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 122:2003;394-403
14. Kotasek D., Steger G., Faught W., Underhill C., Poulsen E., Colowick A.B., et al. Aranesp 980291 Study Group Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomized study. Eur J Cancer. 39:2003;2026-2034
15. Smith R.E. Jr., Tchekmedyian N.S., Chan D., Meza L.A., Northfelt D.W., Patel R., et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 88:2003;1851-1858
16. Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., et al. Aranesp 980297 Study Group Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 94:2002;1211-1220
17. Glaspy J., Jadeja J.S., Justice G., Kessler J., Richards D., Schwartzberg L., et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 84(Suppl):2001;17-23
18. Smith R.E. Jr., Jaiyesimi I.A., Meza L.A., Tchekmedyian N.S., Chan D., Griffith H., et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 84(Suppl):2001;24-30
19. Glaspy J.A., Tchekmedyian N.S. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Huntingt). 16:2002;23-29
20. Mirtsching B., Charu V., Vadhan-Raj S., Colowick A.B., Rossi G., Tomita D., et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia: results of a combined analysis. Oncology (Huntingt). 16:2002;31-36
21. Vansteenkiste J., Poulsen E., Rossi G., Glaspy J. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Huntingt). 16:2002;45-55
22. Hedenus M., Hansen S., Taylor K., Arthur C., Emmerich B., Dewey C., et al. Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol. 119:2002;79-86
23. Glaspy J.A., Jadeja J.S., Justice G., Kessler J., Richards D., Schwartzberg L., et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 87:2002;268-276
24. Lerner G., Kale A.S., Warady B.A., Jabs K., Bunchman T.E., Heatherington A., et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol. 17:2002;933-937
25. De Palo T., Giordano M., Palumbo F., Bellantuono R., Messina G., Colella V., et al. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol. 19:2004;337-340
26. Shannon K.M., Keith J.F., Mentzer W.C., Ehrenkranz R.A., Brown M.S., Widness J.A., et al. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics. 95:1995;1-8
27. Maier R.F., Obladen M., Muller-Hansen I., Kattner E., Merz U., Arlettaz R., et al. Early treatment with erythropoietin β- ameliorates anemia and reduces transfusion requirements in infants with birth weights below 1000 g. J Pediatr. 140:2002;8-15
28. Ohls R.K. Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Padiatr Drugs. 4:2002;111-121
29. Ohls R.K., Dai A. The effect of Aranesp on the growth of fetal and neonatal erythroid progenitors. Blood. 102:2003;18b
30. Ohls R.K., Veerman M.W., Christensen R.D. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution. J Pediatr. 128:1996;518-523
31. Grasso G., Buemi M., Alafaci C., Sfacteria A., Passalacqua M., Sturiale A., et al. Beneficial effects of systemic administration of recombinant human erythropoietin in rabbits subjected to subarachnoid hemorrhage. Proc Natl Acad Sci USA. 99:2002;5627-5631
32. Solaroglu I., Solaroglu A., Kaptanoglu E., Dede S., Haberal A., Beskonakli E., et al. Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst. 19:2003;19-22